Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Neurology

Volumn 85, Issue 8, 2015, Pages 692-700

  Liu, Enchi ^a   Schmidt, Mark E ^b   Margolin, Richard ^a   Sperling, Reisa ^c   Koeppe, Robert ^d   Mason, Neale S ^e   Klunk, William E ^e   Mathis, Chester A ^e   Salloway, Stephen ^f   Fox, Nick C ^g   Hill, Derek L ^h   Les, Andrea S ^h   Collins, Peter ^a   Gregg, Keith M ^a   Di, Jianing ^a   Lu, Yuan ^a   Tudor, I Cristina ^a   Wyman, Bradley T ⁱ   Booth, Kevin ⁱ   Broome, Stephanie ^a   Yuen, Eric ^a   Grundman, Michael ^b,j   Brashear, H Robert ^a   more..

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b San Diego   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f BUTLER HOSPITAL   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h IXICO PLC   (United Kingdom)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BAPINEUZUMAB; CARRIER PROTEIN; PITTSBURGH COMPOUND B; PLACEBO; BENZOTHIAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN RADIOGRAPHY; BRAIN REGION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FRONTAL CORTEX; FUNCTIONAL NEUROIMAGING; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; PHASE 3 CLINICAL TRIAL; PONS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TEMPORAL CORTEX; BRAIN CORTEX; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; APOLIPOPROTEIN E4; BENZOTHIAZOLES; CEREBRAL CORTEX; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84940040128     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001877     Document Type: Article

References (20)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound B. Ann Neurol 2004;55:306-319.
2. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73: 2061-2070.
3. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebocontrolled, ascending-dose study. Lancet Neurol 2010; 9:363-372.
4. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69:1002-1010.
5. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-333.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
8. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
9. Collins DL, Zijdenbos AP, Kollokian V, et al. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 1998;17:463-468.
10. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 1999;18:712-721.
11. Modat M, Ridgway GR, Taylor ZA, et al. Fast free-form deformation using graphics processing units. Computer Methods Programs Biomed 2010;98:278-284.
12. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
13. Cardoso MJ, Clarkson MJ, Ridgway GR, et al. LoAd: a locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
14. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-435.
15. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9:S72-S83.
16. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-321.
17. Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry 2010;68:879-884.
18. Schmidt ME, Chiao P, Klein G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement (in press 2015).
19. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008;63: 621-631.
20. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69:198-207.